Nektar Therapeutics (NKTR) Operating Expenses (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Operating Expenses of $49.9 million for Q1 2026, up 1018.92% year-over-year from $4.5 million in Q1 2025, and up 0.9% quarter-over-quarter from $49.5 million in Q4 2025.
Nektar Therapeutics (NKTR) Operating Expenses (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Operating Expenses history runs 17 years deep, the most recent figure standing at $49.9 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 1018.92% year-over-year to $49.9 million; the TTM figure through Mar 2026 stood at $147.0 million (up 219.76% YoY), while the FY2025 annual figure was $195.3 million, up 422.19% from the prior year.
- Operating Expenses for Q1 2026 stood at $49.9 million, up from $49.5 million in the prior quarter.
- The five-year high for Operating Expenses was $174.4 million in Q2 2022, with the low at -$151.4 million in Q4 2024.
- The 5-year median for Operating Expenses is $49.9 million (2026), against an average of $41.1 million.
- The sharpest annual moves came in 2023 and 2026: Operating Expenses slumped 297.43% in 2023, then jumped 1018.92% in 2026.
- Nektar Therapeutics' Operating Expenses stood at $74.5 million in 2022, then plunged by 297.43% to -$147.1 million in 2023, then dropped by 2.94% to -$151.4 million in 2024, then jumped by 132.68% to $49.5 million in 2025, then gained by 0.9% to $49.9 million in 2026.
- Business Quant data shows NKTR's Operating Expenses at $49.9 million in Q1 2026, $49.5 million in Q4 2025, and $43.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | 49.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49.92 Mn |
| Dec 31, 2025 | 49.47 Mn |
| Sep 30, 2025 | 43.46 Mn |
| Jun 30, 2025 | 4.11 Mn |
| Mar 31, 2025 | 4.46 Mn |
| Dec 31, 2024 | -151.39 Mn |
| Sep 30, 2024 | 5.38 Mn |
| Jun 30, 2024 | 18.84 Mn |
| Mar 31, 2024 | 57.07 Mn |
| Dec 31, 2023 | -147.07 Mn |
| Sep 30, 2023 | 69.01 Mn |
| Jun 30, 2023 | 71.10 Mn |
| Mar 31, 2023 | 156.30 Mn |
| Dec 31, 2022 | 74.49 Mn |
| Sep 30, 2022 | 77.93 Mn |
| Jun 30, 2022 | 174.42 Mn |
| Mar 31, 2022 | 141.38 Mn |
| Dec 31, 2021 | 137.92 Mn |
| Sep 30, 2021 | 138.52 Mn |
| Jun 30, 2021 | 138.54 Mn |